Ceapro Inc V.CZO

RE:RE:RE:RE:RE:RE:RE:RE:RE:Gilles destroyer of shareholders

[prophetoffactz]

boazklinghorn wrote: TLDR

That means everyone should read it twice so here it is again...

"One thing I do know is that despite this avalanche of BS Gilles has never bet on himself."

Gilles's never sold a single share in over a decade. How many President's and CEO's can make that statement? His holdings have only grown over time. He's dedicated the most important years of his professional career to this company. Over one decade. His vision has been consistent from developing a profitable base business, to using the ingredients in the base business to develop pharmaceutical products. He successfully developed the best in class pharma-grade oat beta glucan pill and brought it to trials. He has developed the pharma-grade avenanthramide and now it is in clinical trials. There is a lot of independent research supporting the potential of avenanthramide. For both clinical trials he's used world class Dr. Jean-Claude Tardif. Dr. Tardif participated in the development of the first FDA approved heart disease medication targeting inflammation. He was also in charge of the world's largest outpatient clinical trial for COVID. Who better for CZO's avenanthramide clinical trial. While developing PGX for oat beta glucan PGX-YBG was also discovered with McMaster which is a leading research university in the world. Dr. Ask, now with the second largest pharma company in the world, and Dr. Kolb have both expressed thier excitement. Dr. Kolb said it could profoundly alter the landscape for treating fibrosis. The Canadian government has provided significant funding over time for developing PGX. PGX-Alginate also sets a new standard in an established market. CZO and Symrise have also had a long and successful product development relationship that Symrise has complemented as numerous product applications have been developed over time. Now they are about to launch powder formulations of oat beta glucan and avenanthramide allowing CZO to reach new global markets. Dr. Li of the Angiogenesis Foundation has complemented the wound healing science saying CZO has already past the gold standard animal model other companies use before human trials and likened the potential to Intel Inside. In addition to the signficant financial support over time from the Canadian government CZO has attracted Ronnie Miller from the world's largest biotech company. He's been called a Canadian pharmaceutical icon. 

"Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”"

As CZO's pipeline reaches key milestones the next stage is here and Mr. Miller is "thrilled" with the "exciting" transaction and the path forward to drive significant growth. 

“We are thrilled with this exciting transaction to merge with Aeterna and combine two complementary companies and teams, in support of our plan to drive significant growth,” said Ronnie Miller, Chairman of Ceapro. “After careful consideration, we believe this transaction is the best way forward for Ceapro and our valued shareholders.”

Gilles has consistently backed his vision. He's put in the time - over one decade.  He's ploughed the profits from the base business into this vision and didn't have to. He could have changed visions. The Canadain government has provided increasing support over time. Key opinion leaders like Dr. Tardif, Dr. Kolb, and Dr. Li have backed his science. Go to Pubmed and see the literature corroborating the scinece in general. Gilles gets nothing from his shares and options if this investment doesn't work out. He would have wasted the best years of his life. He has been validated by experts. The profits from the base buisness could have been put elsewhere. Now it's time for the next level and he's patiently watched AEZS for the right time. He knows CZO and EAZS better than anyone and now is the time to take it to the next level. All of the pieces come together for a decade long vision as the pipeline is now reaching key events and commercial decisions. 

Gilles Gagnon, Chief Executive Officer of Ceapro, added: “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs, while achieving Ceapro’s previously stated objective of expanding further into the pharmaceutical space, which we will be able to do via the exciting projects Aeterna has been developing, even as we seek to extract additional value from Ceapro’s core technologies. This is an exciting day for stakeholders of both companies who share a bright future together.”